PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma
Abstract This analysis describes the pharmacokinetic/pharmacodynamic (PK/PD) modeling framework that supported selection of the isatuximab (anti‐CD38 monoclonal antibody) dosing regimen alongside its early clinical development in patients with relapsed/refractory multiple myeloma (RRMM). The PK/PD m...
Spremljeno u:
Glavni autori: | , , , , , , , , , |
---|---|
Format: | Knjiga |
Izdano: |
Wiley,
2021-08-01T00:00:00Z.
|
Teme: | |
Online pristup: | Connect to this object online. |
Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|
Internet
Connect to this object online.3rd Floor Main Library
Signatura: |
A1234.567 |
---|---|
Primjerak 1 | Dostupno |